Serum ceruloplasmin can predict liver fibrosis in hepatitis B virus-infected patients
| Autor: | Yueyong Zhu, Meng-Xin Lin, Yu-Rui Liu, Na-Ling Kang, Zu-Xiong Huang, Jie-Min Zhang, Da-Wu Zeng, Xu-Dong Chen |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
Adult
Liver Cirrhosis Male Hepatitis B virus HBsAg medicine.medical_specialty Cirrhosis Liver fibrosis medicine.disease_cause Gastroenterology 03 medical and health sciences Serum ceruloplasmin Hepatitis B Chronic 0302 clinical medicine Retrospective Study Internal medicine medicine Humans Platelet Retrospective Studies Receiver operating characteristic biology business.industry Noninvasive model Ceruloplasmin Alanine Transaminase General Medicine Middle Aged medicine.disease Receiver-operating characteristic Chronic hepatitis B infection Serum alanine aminotransferase Liver ROC Curve 030220 oncology & carcinogenesis biology.protein Female 030211 gastroenterology & hepatology business Biomarkers |
| Zdroj: | World Journal of Gastroenterology |
| ISSN: | 1007-9327 |
| DOI: | 10.3748/wjg.v26.i27.3952 |
| Popis: | Background The presence of significant liver fibrosis in hepatitis B virus (HBV)-infected individuals with persistently normal serum alanine aminotransferase (PNALT) levels is a strong indicator for initiating antiviral therapy. Serum ceruloplasmin (CP) is negatively correlated with liver fibrosis in HBV-infected individuals. Aim To examine the potential value of serum CP and develop a noninvasive index including CP to assess significant fibrosis among HBV-infected individuals with PNALT. Methods Two hundred and seventy-five HBV-infected individuals with PNALT were retrospectively evaluated. The association between CP and fibrotic stages was statistically analyzed. A predictive index including CP [Ceruloplasmin hepatitis B virus (CPHBV)] was constructed to predict significant fibrosis and compared to previously reported models. Results Serum CP had an inverse correlation with liver fibrosis (r = -0.600). Using CP, the areas under the curves (AUCs) to predict significant fibrosis, advanced fibrosis, and cirrhosis were 0.774, 0.812, and 0.853, respectively. The CPHBV model was developed using CP, platelets (PLT), and HBsAg levels to predict significant fibrosis. The AUCs of this model to predict significant fibrosis, advanced fibrosis, and cirrhosis were 0.842, 0.920, and 0.904, respectively. CPHBV was superior to previous models like the aspartate aminotransferase (AST)-to-PLT ratio index, Fibrosis-4 score, gamma-glutamyl transpeptidase-to-PLT ratio, Forn's score, and S-index in predicting significant fibrosis in HBV-infected individuals with PNALT. Conclusion CPHBV could accurately predict liver fibrosis in HBV-infected individuals with PNALT. Therefore, CPHBV can be a valuable tool for antiviral treatment decisions. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|